Richter Syndrome, an aggressive lymphoma occurring in patients with chronic lymphocytic leukaemia (CLL), has a generally poor prognosis and anthracycline-based chemoimmunotherapy regimens designed to treat de novo diffuse large B-cell lymphoma achieve modest clinical benefit. R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) has demonstrated greater activity against aggressive B-cell histologies but has not been studied in Richter Syndrome. We conducted a retrospective cohort study of 46 Richter Syndrome patients treated with first-line R-EPOCH at our institution between 1 January 2006 and 31 May 2014. The median progression-free survival (PFS) was 3Á5 months [95% confidence interval (CI): 2Á0-7Á6] and median overall survival (OS) was 5Á9 months (95% CI: 3Á2-10Á3). Toxicity was high and 30% of patients died without progression or response. Patients with a complex CLL karyotype had significantly shorter PFS and OS (P = 0Á005 and P = 0Á002, respectively). Multivariable analysis identified complex CLL karyotype as the most significant predictor of decreased survival [Hazard ratio (HR) 2Á72, 95% CI: 1Á14-6Á52, P = 0Á025], adjusting for number of prior CLL treatments (P = 0Á036). Richter Syndrome patients with complex CLL karyotype experience poor survival with R-EPOCH treatment and novel approaches are needed for these patients. In contrast, survival of patients without a complex CLL karyotype was similar to patients with de novo diffuse large B-cell lymphoma.
The development of an aggressive lymphoma in patients with chronic lymphocytic leukaemia (CLL), known as Richter Syndrome (RS), is a devastating complication of disease associated with poor clinical outcomes (Richter, 1928; Parikh et al, 2014) . RS affects between 2Á2-10Á7% of CLL patients and the majority of RS patients die of this complication (Mauro et al, 1999; Tsimberidou et al, 2006; Rossi et al, 2008; Fan et al, 2012; Parikh et al, 2013) . Median survival for patients with RS is short, generally between 8-21 months, with only a minority of patients achieving long-term survival (Tsimberidou et al, 2006; Rossi et al, 2011; Tadmor et al, 2014) . A variety of factors have been shown to influence outcomes for RS patients including markers of patient fitness, such as Eastern Cooperative Oncology Group (ECOG) performance status and platelet count, exposure to prior chemotherapy for CLL and, most importantly, clonal relationship of the lymphoma to the underlying CLL (Tsimberidou et al, 2006; Rossi et al, 2011; Parikh et al, 2013; Tadmor et al, 2014) . While the development of targeted agents, such as ibrutinib, has been a major advancement in the treatment of CLL, it has not eliminated RS (Maddocks et al, 2015) .
Anthracycline-based chemoimmunotherapy regimens designed to treat aggressive lymphomas remain the standard treatment for RS (Parikh et al, 2014) . Outcomes with R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) were reported in two small studies resulting in response rates of 50% and 67% and median overall survival (OS) of 15 and 21 months (Tsimberidou et al, 2013; Langerbeins et al, 2014) . A recent prospective study of a similar regimen, CHOP in combination with the anti-CD20 monoclonal antibody ofatumumab followed by ofatumumab maintenance had a short median OS of only 11Á4 months (Eyre et al, 2016) . Attempts to improve on outcomes with more aggressive regimens, such as hyperCVXD (fractionated cyclophosphamide, vincristine, liposomal daunorubicin and dexamethasone), or non-anthracycline regimens, such as OFAR (oxaliplatin, fludarabine, cytarabine and rituximab), have not resulted in significantly longer survival (median 6Á6-10 months). Further, the toxicity of these regimens was substantial; treatment-related mortality was 20% in the group treated with hyperCVXD (Dabaja et al, 2001; Tsimberidou et al, 2003 Tsimberidou et al, , 2008 Tsimberidou et al, , 2013 .
Outside of clinical trials, our group has adopted R-EPOCH (rituximab, etoposide, prednisone, vincristine, cyclophosphamide and doxorubicin) as the institutional standard-of-care for treating RS patients. R-EPOCH is similar to R-CHOP, but with the addition of etoposide and the continuous infusion of etoposide, vincristine and doxorubicin over 96 h rather than bolus dosing (Wilson et al, 1993) . R-EPOCH is effective in more aggressive lymphoma subtypes, such as primary mediastinal B-cell and Burkitt lymphoma, and has demonstrated superior efficacy to R-CHOP in human immunodeficiency virus (HIV)-associated B-cell lymphomas (Dunleavy et al, 2010 (Dunleavy et al, , 2013a Sparano et al, 2010) .
The efficacy of R-EPOCH treatment for RS has never been systematically assessed. To better characterize the effectiveness of this regimen and which patient and disease factors influence treatment outcomes we performed a retrospective analysis of patients treated at our institution with first-line R-EPOCH for RS.
Methods
The Ohio State University Cancer Institutional Review Board approved this study by expedited review under a waiver of informed consent. All patients with a confirmed pathological diagnosis of both CLL and B-cell non-Hodgkin lymphoma who received initial lymphoma treatment with R-EPOCH between 1 January 2006 and 31 May 2014 were included in the analysis. All patients received at least one dose of R-EPOCH treatment, and were seen at the Ohio State University during their treatment. Patients without a confirmed diagnosis of CLL or whose lymphoma diagnosis predated their CLL diagnosis were excluded. Data were retrospectively abstracted from medical records.
The date of RS diagnosis was considered to be the date of initial biopsy demonstrating lymphoma pathology. CLL characteristics were captured at the time of RS diagnosis, and CLL karyotype was that performed most recent to, but preceding, RS diagnosis, or a karyotype done at the time of RS diagnosis on tissue not histologically involved with lymphoma.
All karyotypes were performed by the Ohio State University cytogenetics laboratory and were stimulated and prepared according to a standard method. Cells from bone marrow or peripheral blood (2Á0 9 10 6 cells/ml) were incubated in RPMI 1640 medium (Fischer Scientific, Houston, TX) with 2% L-Glutamine (Gibco Invitrogen, Carlsbad, CA), supplemented with 20% fetal bovine serum (Hyclone Laboratories, Logan, TX) and 2% penicillin and streptomycin (Gibco Invitrogen). The mitogens used were pokeweed mitogen (PWM, 10 lg/ml, Sigma Aldrich, St. Louis, MO), phorbol 12-myristate 13-acetate (PMA, 40 ng/ml, Sigma Aldrich), and CpG ODN 685 (20 lg/ml, synthesized by Sigma Aldrich). CpG ODN 685 alone (20 lg/ml) was used in a second culture. The mitogens were added to the cultures, and the cells were incubated for 72 h under standard laboratory conditions. All samples were harvested, fixed, G-banded using trypsin and stained with Wright stain according to standard laboratory procedures. Twenty metaphases were completely analysed whenever possible. Karyotypes were described according to the clinically reported nomenclature, which was the International System for Human Cytogenetic Nomenclature (ISCN) 2009 or ISCN 2013 during the study timeframe (Shaffer et al, 2009; Shaffer et al, 2013) . A complex karyotype was defined as a karyotype with at least three unrelated abnormalities. All patients who had available imaging were assessed for bulk of lymphoma by review of computed tomography (CT) scan reports at the time of initial lymphoma diagnosis. Determination of extranodal disease was based on CT and positron emission tomography (PET) scan reports where available. Baseline laboratory values were those reported for day 1 of the first cycle of R-EPOCH treatment.
Toxicity of R-EPOCH was assessed by reviewing the frequency of adverse events including infection, hospitalization, intensive care unit stay, neutropenic fever, fever without neutropenia, mucositis limiting oral intake, ileus, blood products transfusion, and/or fatigue requiring treatment delay. Events were recorded for each cycle of R-EPOCH given. R-EPOCH treatment outcomes including response to R-EPOCH treatment and lymphoma progression were recorded as documented by the treating physician and not secondarily verified.
Patient characteristics were described using summary statistics. Progression-free survival (PFS) was calculated from the date of RS diagnosis to the date of progression or death from any cause, censoring patients without an event at time of last follow-up. Patients who went on to receive a second type of treatment for RS prior to disease progression were not censored for PFS analysis. OS was calculated from the date of RS diagnosis to the date of death, censoring patients who were alive at last follow-up. Estimates of PFS and OS were obtained using the Kaplan-Meier method and the differences in curves were compared by the log-rank test.
Proportional hazards models were used to evaluate the association between clinical factors and PFS and OS. Univariable models were first fit, then multivariable models were built using forward selection where variables entered the model based on statistical significance (P < 0Á05). Age, months from CLL diagnosis to RS diagnosis, complex CLL karyotype, fluorescence in situ hybridization (FISH) panel positive for deletion(17p13.1), IGHV unmutated status, ECOG performance status at diagnosis, number of prior CLL treatments, tumour size ≥5 cm, and baseline laboratory values including absolute neutrophil count, serum creatinine, albumin, total bilirubin, lactate dehydrogenase (LDH), and platelet count were considered for inclusion. In a similar manner, logistic regression was used to model response and risk for toxicities.
Results

Patient and disease characteristics
Forty-six patients, including 25 (54%) men and 21 (46%) women, met the inclusion criteria. Baseline characteristics for all patients, including CLL experience and disease risk factors as well as laboratory values, are found in Table I . The cohort was enriched for CLL cases featuring characteristics associated with more aggressive CLL (Hamblin et al, 1999; Dohner et al, 2000; Thompson et al, 2014) .
The most common lymphoma histology was diffuse large B-cell lymphoma, which was found in 42 (91%) cases. Two patients had early large-cell/prolymphocytic transformation and one each had plasmablastic lymphoma or high-grade Bcell lymphoma. The lymphoma was known to involve extranodal sites in 20 (43%) patients. Thirty-eight of the patients had CT scans at lymphoma diagnosis and were evaluable for lymphoma bulk. Of those, 16 (42%) had disease between 5-10 cm and 8 (21%) had disease ≥10 cm in size. Thirty-nine patients underwent PET scan and the median maximal standard uptake value reported anywhere on the scan was 14Á4 (range 2Á8-46Á3).
ECOG performance status at RS diagnosis was available for 28 (61%) patients, and was 0 for 5 patients, 1 for 13 patients, 2 for 7 patients, 3 for 2 patients and 4 for 1 patient. At the time of R-EPOCH initiation, 12 (26%) patients were hospitalized for reasons other than to receive a diagnostic biopsy or start treatment.
Treatment disposition, adverse events, and response
The median number of R-EPOCH cycles completed was 2 (range 1-6), and a significant fraction of patients (18/46 or Nine responding patients received less than 6 cycles of R-EPOCH for various reasons. The majority ended treatment when the desired response was achieved or due to toxicities unacceptable to the treating physician or patient. This included 4 patients who discontinued R-EPOCH to start a new treatment prior to developing progressive disease: 1 patient ended treatment to receive radiation therapy after 1 cycle, 2 stopped R-EPOCH to undergo allogeneic stem cell transplant, 1 patient was deemed to have an inadequate response by the treating physician and was started on a second-line chemoimmunotherapy regimen. One hundred and fourteen of a total of 127 (90%) cycles given were evaluable for adverse events. Adverse events were most common during cycle 1 and decreased in frequency during subsequent cycles. During cycle 1, 29 of 40 evaluable patients (73%) had an adverse event compared to 17/29 (59%) during cycle 2, 7/15 (47%) during cycle 3, 4/12 (33%) during cycle 4, 2/11 (18%) during cycle 5, and 1/7 (14%) in cycle 6. Many patients experienced more than one adverse event. Hospitalization complicated 22% of cycles and included intensive care unit stay 4%, neutropenic fever 17%, fever without neutropenia 5% and infection 21%. No association between age at RS diagnosis or baseline absolute neutrophil count and the adverse events of infection, neutropenic fever or hospitalization were detected (P > 0Á15).
Treatment response was known for 44 patients. Seventeen patients (39%) demonstrated a response as assessed by the treating clinician, 14 patients (32%) had lymphoma progression and 13 patients (30%) died without confirmed or suspected lymphoma progression. Kaplan-Meier curves for PFS and OS are shown in Fig 1. Estimated median PFS after R-EPOCH was only 3Á5 months [95% confidence interval (CI): 2Á0-7Á6] and median OS was 5Á9 months (95% CI: 3Á2-10Á3). Only 9 (20%) patients were alive and without lymphoma progression at last follow-up, which was a median of 39 months (range 13-54) for these patients. Of those 9 patients, 8 did not require a lymphoma treatment other than R-EPOCH and 1 patient discontinued R-EPOCH after 1 cycle owing to toxicity and received radiation therapy.
Modelling risk for disease progression and death
Univariable analysis identified several variables that were strongly or moderately associated with OS, including: complex CLL karyotype, deletion(17p13.1) by FISH, number of prior CLL treatments, ECOG performance status at RS diagnosis, and baseline laboratory values for platelet count, serum creatinine, albumin and total bilirubin (Table II) . Complex CLL karyotype, deletion(17p13.1) and number of prior CLL treatments were most strongly associated with inferior OS (P < 0Á01). Results for univariable analysis for PFS were similar with the exception that total bilirubin was not a significant association.
Complex CLL karyotype has not been previously described as an adverse prognostic feature in RS, and Kaplan-Meier curves are shown according to presence or absence of complex CLL karyotype in Fig 2. Patients with a complex CLL karyotype had significantly shorter PFS and OS (P = 0Á005 and P = 0Á002, respectively). The estimated 1-year PFS and OS for patients with a complex CLL karyotype were 11% (95% CI: 3-25%) and 18% (95% CI: 7-34%) respectively, compared to 57% (95% CI: 28-78%) and 71% (95% CI: 41-88%) for those without a complex CLL karyotype, In the multivariable model for OS, only complex CLL karyotype (HR 2Á72, 95% CI: 1Á14-6Á52, P = 0Á025) and number of prior CLL treatments (HR 1Á17, 95% CI: 1Á01-1Á35, P = 0Á036) provided independent prognostic information (Table II) . Deletion(17p13.1) was strongly associated with OS in the univariable analysis but did not provide additional information in the multivariable model independent of complex karyotype and number of prior therapies. This is probably attributable to the high degree of correlation with complex CLL karyotype (P < 0Á0001). There was only one patient with deletion(17p13.1) who did not also have a complex CLL karyotype, limiting the ability to analyse the relative contribution of each variable. For PFS, the variable most strongly associated with clinical outcome was complex CLL karyotype; once this variable was in the model, no other variable provided significant additional prognostic information.
Discussion
In a large cohort of CLL patients treated within the last decade for RS with first-line R-EPOCH chemoimmunotherapy, the reported median PFS of 3Á9 months and OS of 5Á9 months compares unfavourably with other regimens (Dabaja et al, 2001; Tsimberidou et al, 2003 Tsimberidou et al, , 2008 Tsimberidou et al, , 2013 Langerbeins et al, 2014; Eyre et al, 2016) . The toxicity of R-EPOCH was likewise significant with a high number of patients (73%) experiencing an adverse event in the first cycle and 30% dying without lymphoma progression. While some of these deaths without progression are probably attributable to illness severity or poor baseline patient fitness, disease control also remained poor with nearly a third of patients progressing during treatment. Only 39% of patients completed the first cycle of R-EPOCH, which is in keeping with two prospective clinical trials with hyper-CVXD in RS where 18% and 24% of patients respectively completed only one cycle of treatment (Dabaja et al, 2001 ; Tsimberidou et al, 
CLL, chronic lymphocytic leukaemia; ECOG PS, Eastern Cooperative Oncology Group performance status; FISH, fluorescence in situ hybridization; IGHV, immunoglobulin gene heavy chain; LDH, lactate dehydrogenase; RS, Richter syndrome. *30% data missing on IGHV mutation, 40% missing on ECOG PS at diagnosis. †Forward selection was used and variables with P < 0Á05 were retained in the final multivariable model. . Given the relative superior fitness of a clinical trial population compared to our retrospectively reviewed patients, our finding is not unexpected. Although lacking the rigor of a prospective clinical trial, our data do not support the contention that R-EPOCH is superior to previously studied anthracycline-based regimens, such as standard R-CHOP, and demonstrate that our current standard of care is insufficient for a large number of RS patients. Our analysis is novel in identifying complex CLL karyotype as the characteristic most strongly associated with poor survival, effectively identifying the group of patients who are unlikely benefit from first-line chemoimmunotherapy as those with this feature. In multivariable analysis complex CLL karyotype superseded many characteristics previously found to be prognostic (Tsimberidou et al, 2006; Rossi et al, 2011; Parikh et al, 2013; Tadmor et al, 2014) . This finding stratifies CLL patients into two groups with vastly different survival experiences and further study may show that this finding supersedes other prognostic markers. The only other characteristic which was associated with survival independent of complex CLL karyotype was number of prior CLL treatments. While our cohort was not of a sufficient size to draw statistically sound conclusions regarding the association of outcomes with specific CLL therapies, this does demonstrate that exposure to prior antineoplastic agents is adverse.
R-EPOCH for
One explanation for our finding regarding complex CLL karyotype is that the disease biology of RS in these cases may be more aggressive, and therefore clinical and laboratory markers of disease severity and poor survival are strongly correlated with this characteristic. Clonal relationship of the lymphoma to the underlying CLL has previously been described as an important prognostic factor in RS (Rossi et al, 2011) . We have insufficient information to establish the clonal relationship of the lymphoma in our patients to the underlying CLL, and are unable to determine if clonal relationship correlates with complex CLL karyotype. If known, that information could add significantly to our findings, especially if clonal relationship and presence of a complex CLL karyotype are correlated.
As a positive finding in this study, our patients without a complex CLL karyotype have an estimated 1-year OS of 71%. This is similar to de novo diffuse large B-cell lymphoma patients, suggesting that first-line anthracycline-based chemoimmunotherapy may be appropriate for this subset of RS patients.
Our findings regarding complex CLL karyotype have clinical utility for counselling RS patients regarding prognosis, planning first-line treatment strategies, electing for allogeneic stem cell transplant in eligible patients, and designing prospective clinical trials for this high-risk patient population. Based on these findings, we have revised our institutional approach to RS and recommend treatment on a clinical trial with novel or targeted agents to patients with a complex CLL karyotype. We continue to recommend R-EPOCH as a first-line treatment to fit patients without a complex CLL karyotype. Given the extremely poor survival of RS patients with a complex CLL karyotype in our series, treatment approaches based on cytotoxic chemotherapy appear unlikely to improve outcomes and new therapeutic options for these patients are urgently needed.
There are several limitations of this study. First, this is a retrospective study where treatment response and progression of lymphoma were not as rigorously assessed as during a prospective clinical trial. Consequently, both response and progression data are less reliable. Second, R-EPOCH administration was likewise not standardized, which could lead to variability in treatment, although this variability better captures the realities of clinical practice. Third, we used clinically reported cytogenetic data in our analysis. Due to the retrospective nature of this work, biological samples were not available for a comparison of genetic differences between the CLL and lymphoma cells or other biological characteristics previously shown to be prognostic in RS such as TP53 disruption. This would be of interest given our findings regarding complex CLL karyotype. Lastly, the illness severity in our cohort was high, and some patients were less fit than typical clinical trial patients. This may be reflected in our finding that adverse events were less common in later cycles as more fit patients were probably better able to tolerate continued R-EPOCH treatment.
Overall, our findings suggest that in a real-world population of RS patients, first-line R-EPOCH does not provide a benefit above R-CHOP or other chemoimmunotherapy regimens studied in this population. We also identified patients with a complex CLL karyotype as having particularly poor survival. Future investigations should consider novel therapeutic strategies for RS, particularly for patients with a complex CLL karyotype.
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